GSK Acquires Exclusive Rights to Syndivia’s Next-Generation ADC for Advanced Prostate Cancer

GSK plc has entered into an agreement with Syndivia, a private biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), granting GSK exclusive worldwide rights to develop and commercialize a preclinical ADC therapy for metastatic castration-resistant prostate cancer (mCRPC).

Prostate cancer affects roughly 1.4 million men globally each year, with up to 20% progressing to advanced, castration-resistant disease within five years. For those with mCRPC, treatment options remain limited, often offering modest efficacy and challenging tolerability. The five-year survival rate for patients with this condition is only about 30%, with a median survival of two years.

The novel ADC utilizes Syndivia’s proprietary GeminiMab conjugation technology, which has demonstrated strong anti-tumor activity and a favorable safety profile in preclinical studies. The therapy showed the ability to shrink tumors without significantly increasing side effects, even at higher doses—suggesting best-in-class potential for targeted prostate cancer treatment.

According to Hesham Abdullah, Senior Vice President and Global Head of Oncology R&D at GSK, “Prostate cancer represents a significant health burden and an emerging area of growth for GSK, where targeted therapies are urgently needed in metastatic castration-resistant settings. The addition of this ADC builds on GSK’s growing portfolio and strengths in tumor-targeted technologies, including our B7-H3-targeting ADC, GSK’227.”

Sasha Koniev, Chief Executive Officer of Syndivia, said the collaboration marks a major milestone for the company. “We are proud that GSK will advance this programme on a global scale. This agreement underscores the value of our GeminiMab ADC platform and the opportunity to bring a promising new therapy to patients with pressing unmet medical needs,” he said.

The partnership reinforces GSK’s commitment to expanding its oncology pipeline, which includes innovative ADCs, small molecules, and T-cell engager therapies targeting multiple cancer types and disease stages.